Farmers & Merchants Investments Inc. lifted its holdings in shares of Bristol-Myers Squibb Co (NYSE:BMY) by 3.8% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 105,664 shares of the biopharmaceutical company’s stock after purchasing an additional 3,881 shares during the quarter. Farmers & Merchants Investments Inc.’s holdings in Bristol-Myers Squibb were worth $6,735,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Renaissance Technologies LLC raised its position in Bristol-Myers Squibb by 108.5% in the 2nd quarter. Renaissance Technologies LLC now owns 13,488,200 shares of the biopharmaceutical company’s stock valued at $751,563,000 after purchasing an additional 7,020,200 shares in the last quarter. Franklin Resources Inc. raised its position in shares of Bristol-Myers Squibb by 185.2% during the 2nd quarter. Franklin Resources Inc. now owns 6,098,935 shares of the biopharmaceutical company’s stock worth $339,830,000 after acquiring an additional 3,960,191 shares in the last quarter. Janus Henderson Group PLC raised its position in shares of Bristol-Myers Squibb by 2,990.5% during the 2nd quarter. Janus Henderson Group PLC now owns 3,634,128 shares of the biopharmaceutical company’s stock worth $202,494,000 after acquiring an additional 3,516,536 shares in the last quarter. Arrowstreet Capital Limited Partnership raised its position in shares of Bristol-Myers Squibb by 42,071.5% during the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 3,331,549 shares of the biopharmaceutical company’s stock worth $185,634,000 after acquiring an additional 3,323,649 shares in the last quarter. Finally, Ameriprise Financial Inc. raised its position in shares of Bristol-Myers Squibb by 18.7% during the 1st quarter. Ameriprise Financial Inc. now owns 15,547,051 shares of the biopharmaceutical company’s stock worth $845,504,000 after acquiring an additional 2,451,390 shares in the last quarter. Institutional investors and hedge funds own 69.66% of the company’s stock.

A number of research analysts recently issued reports on the company. Vetr downgraded Bristol-Myers Squibb from a “buy” rating to a “hold” rating and set a $63.67 price target on the stock. in a research note on Thursday, September 28th. Jefferies Group restated a “buy” rating and set a $72.00 price target on shares of Bristol-Myers Squibb in a research note on Wednesday, September 27th. BMO Capital Markets set a $49.00 price target on Bristol-Myers Squibb and gave the stock a “sell” rating in a research note on Monday, December 11th. Piper Jaffray Companies restated a “hold” rating and set a $60.00 price target on shares of Bristol-Myers Squibb in a research note on Friday, October 27th. Finally, Cowen restated a “hold” rating and set a $65.00 price target on shares of Bristol-Myers Squibb in a research note on Tuesday, September 19th. One research analyst has rated the stock with a sell rating, ten have assigned a hold rating and eleven have issued a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus target price of $64.93.

Bristol-Myers Squibb Co (NYSE:BMY) opened at $61.20 on Thursday. The stock has a market capitalization of $100,755.26, a price-to-earnings ratio of 20.80, a P/E/G ratio of 2.33 and a beta of 1.18. Bristol-Myers Squibb Co has a 1-year low of $46.01 and a 1-year high of $66.10. The company has a current ratio of 1.59, a quick ratio of 1.46 and a debt-to-equity ratio of 0.47.

Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.77 by ($0.02). Bristol-Myers Squibb had a return on equity of 32.41% and a net margin of 20.56%. The company had revenue of $5.25 billion during the quarter, compared to analyst estimates of $5.20 billion. During the same period last year, the firm earned $0.77 earnings per share. The business’s revenue was up 6.7% compared to the same quarter last year. analysts predict that Bristol-Myers Squibb Co will post 2.99 EPS for the current year.

The business also recently declared a quarterly dividend, which will be paid on Thursday, February 1st. Stockholders of record on Friday, January 5th will be issued a $0.40 dividend. This represents a $1.60 dividend on an annualized basis and a dividend yield of 2.61%. This is a boost from Bristol-Myers Squibb’s previous quarterly dividend of $0.39. The ex-dividend date is Thursday, January 4th. Bristol-Myers Squibb’s payout ratio is 61.42%.

In related news, Director Theodore R. Samuels II purchased 4,000 shares of the business’s stock in a transaction dated Friday, December 15th. The stock was bought at an average cost of $62.30 per share, with a total value of $249,200.00. Following the completion of the acquisition, the director now directly owns 22,000 shares in the company, valued at approximately $1,370,600. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Sandra Leung sold 156,582 shares of the business’s stock in a transaction on Monday, December 4th. The stock was sold at an average price of $63.37, for a total value of $9,922,601.34. Following the completion of the transaction, the executive vice president now directly owns 584,373 shares of the company’s stock, valued at $37,031,717.01. The disclosure for this sale can be found here. Insiders own 0.23% of the company’s stock.

WARNING: “Bristol-Myers Squibb Co (BMY) Shares Bought by Farmers & Merchants Investments Inc.” was originally reported by Watch List News and is owned by of Watch List News. If you are viewing this piece on another site, it was copied illegally and republished in violation of US & international copyright & trademark law. The correct version of this piece can be accessed at https://www.watchlistnews.com/bristol-myers-squibb-co-bmy-shares-bought-by-farmers-merchants-investments-inc/1775626.html.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.